Editorial| Volume 22, ISSUE 9, P1777, September 2021

Download started.


AMDA Position Statement on Aducanumab

  • Lea C. Watson
    Address correspondence to Lea C. Watson, MD, MPH, Co-chair, Behavioral Health Council, AMDA 10500 Little Patuxent Parkway, Suite 210 Columbia, MD 21044.
    Behavioral Health Council, AMDA, Columbia, MD, USA

    Geriatric Psychiatry Consultation and Training, Denver, CO, USA
    Search for articles by this author
  • Richard Juman
    Behavioral Health Council, AMDA, Columbia, MD, USA

    Director of Behavioral Health Policy and Regulations, TeamHealth, Accord, NY, USA
    Search for articles by this author
  • AMDA Board of Directors
      AMDA–The Society for Post-Acute and Long-Term Care Medicine is compelled to comment on the recent approval of the controversial parenteral Alzheimer's dementia (AD) medication, aducanumab. After considering the evidence, we conclude that the aducanumab trials did not adequately demonstrate safety or efficacy. Moreover, aducanumab has only been studied in individuals with mild cognitive impairment or early-stage dementia due to hyperamyloidosis (eg, AD) and has never been tested in a population representative of nursing home residents. We therefore cannot endorse recommending or prescribing aducanumab to post-acute and long-term care (PALTC) residents and patients.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Journal of the American Medical Directors Association
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Reichman W.
        Aducanumab and Alzheimer’s disease: IPA's position on controversial FDA approval.
        (Available at:)
        • Institute for Clinical and Economic Review
        ICER issues statement on the FDA’s approval of aducanumab for Alzheimer’s disease.
        (Available at:)
        • Hollman P.
        • Lundebjerg N.E.
        Letter to FDA Biogen drug for Alzheimer’s.
        (Available at:)
        • Powell T.
        What a bad day science had.
        (Available at:)
        • Greicius M.
        • Alexander G.C.
        People want an Alzheimer’s drug. This isn’t the one.
        (Available at:)
        • Karlawish J.
        If the FDA approves Biogen’s Alzheimer’s treatment, I won’t prescribe it.
        (Available at:)
        • Alexander G.C.
        • Emerson S.
        • Kesselheim A.S.
        Evaluation of aducanumab for Alzheimer Disease: Scientific evidence and regulatory review involving efficacy, safety, and futility.
        JAMA. 2021; 325: 1717-1718